Incretin Atlas › Trials › HRS9531-T-201 oral ribupatide (NCT06841445)
HRS9531-T-201 oral ribupatide (NCT06841445)
Ribupatide (HRS9531) · obesity
Design
- Molecule(s)
- Ribupatide (HRS9531)
- Population
- obesity
- Phase
- 2
- Participants
- 166
- Duration
- 26 weeks
- Registry
- NCT06841445
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 mg oral QD | obesity china | 26 | 166 | −6.9 % vs −2.3 % Δ −4.6 pp | −6.7 % vs −2.1 % Δ −4.6 pp | — | 0.0 vs 0.0 | — | 11.9 vs 7.5 | 2.4 vs 0.0 | 2.4 vs 2.5 | −6.1 vs −3.9 | press release |
| 25 mg oral QD | obesity china | 26 | 166 | −12.1 % vs −2.3 % Δ −9.8 pp | −11.9 % vs −2.1 % Δ −9.8 pp | — | 0.0 vs 0.0 | — | 22.7 vs 7.5 | 11.4 vs 0.0 | 4.5 vs 2.5 | −6.4 vs −3.9 | press release |
| 50 mg oral QD | obesity china | 26 | 166 | −12.1 % vs −2.3 % Δ −9.8 pp | −11.4 % vs −2.1 % Δ −9.3 pp | — | 2.5 vs 0.0 | — | 20.0 vs 7.5 | 7.5 vs 0.0 | 0.0 vs 2.5 | −5.1 vs −3.9 | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (21)
- 10 mg oral QD · weight_tp · press release
Based on the treatment policy estimand^II at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.7% (10 mg), 11.9% (25 mg), and 11.4% (50 mg)
- 10 mg oral QD · nausea · abstract
Nausea 5 (11.9) 10 (22.7) 8 (20.0) 3 (7.5)
- 10 mg oral QD · vomiting · abstract
Vomiting 1 (2.4) 5 (11.4) 3 (7.5) 0
- 10 mg oral QD · sae · abstract
SAEs* 1 (2.4) 2 (4.5) 0 1 (2.5)
- 10 mg oral QD · ae_dc · abstract
TEAEs leading to treatment discontinuation 0 0 1 (2.5)# 0
- 10 mg oral QD · sbp · abstract
SBP, mmHg, LS mean (SE) -6.1 (1.4) -6.4 (1.3) -5.1 (1.4) -3.9 (1.5)
- 10 mg oral QD · weight_eff · press release
Based on the efficacy estimand^I at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg)
- 25 mg oral QD · weight_tp · press release
Based on the treatment policy estimand^II at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.7% (10 mg), 11.9% (25 mg), and 11.4% (50 mg)
- 25 mg oral QD · nausea · abstract
Nausea 5 (11.9) 10 (22.7) 8 (20.0) 3 (7.5)
- 25 mg oral QD · vomiting · abstract
Vomiting 1 (2.4) 5 (11.4) 3 (7.5) 0
- 25 mg oral QD · sae · abstract
SAEs* 1 (2.4) 2 (4.5) 0 1 (2.5)
- 25 mg oral QD · ae_dc · abstract
TEAEs leading to treatment discontinuation 0 0 1 (2.5)# 0
- 25 mg oral QD · sbp · abstract
SBP, mmHg, LS mean (SE) -6.1 (1.4) -6.4 (1.3) -5.1 (1.4) -3.9 (1.5)
- 25 mg oral QD · weight_eff · press release
Based on the efficacy estimand^I at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg)
- 50 mg oral QD · weight_tp · press release
Based on the treatment policy estimand^II at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.7% (10 mg), 11.9% (25 mg), and 11.4% (50 mg)
- 50 mg oral QD · nausea · abstract
Nausea 5 (11.9) 10 (22.7) 8 (20.0) 3 (7.5)
- 50 mg oral QD · vomiting · abstract
Vomiting 1 (2.4) 5 (11.4) 3 (7.5) 0
- 50 mg oral QD · sae · abstract
SAEs* 1 (2.4) 2 (4.5) 0 1 (2.5)
- 50 mg oral QD · ae_dc · abstract
TEAEs leading to treatment discontinuation 0 0 1 (2.5)# 0
- 50 mg oral QD · sbp · abstract
SBP, mmHg, LS mean (SE) -6.1 (1.4) -6.4 (1.3) -5.1 (1.4) -3.9 (1.5)
- 50 mg oral QD · weight_eff · press release
Based on the efficacy estimand^I at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg)
Primary sources
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract hrs9531t201_ada2026_poster.
- Kailera / Hengrui. Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide (GlobeNewswire via BioSpace) [press release]. 2026-02-10. Available from: https://www.biospace.com/press-releases/kailera-therapeutics-and-hengrui-pharma-report-positive-topline-data-from-phase-2-obesity-trial-of-oral-ribupatide
How to cite this page
Medical Adviser's Group. Incretin Atlas: HRS9531-T-201 oral ribupatide (NCT06841445). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-t-201-oral-ribupatide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.